Lukas Biomedical Inc. (TPEX:6814)
Taiwan · Delayed Price · Currency is TWD 23.00
-0.10 (-0.43%)
Aug 4, 2026, 12:47 PM CST
Lukas Biomedical Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 34.75 | 64.71 | 31.8 | 40.26 | 64.81 |
Cash & Short-Term Investments | 34.75 | 64.71 | 31.8 | 40.26 | 64.81 |
Cash Growth | -46.31% | 103.50% | -21.02% | -37.88% | 66.00% |
Accounts Receivable | 11.52 | 9.68 | 10.68 | 12.09 | 18.25 |
Receivables | 11.52 | 9.68 | 10.68 | 12.09 | 18.25 |
Inventory | 35.39 | 38.02 | 36.73 | 42.4 | 26.89 |
Prepaid Expenses | 9.15 | 10.55 | 6.32 | 9.84 | 9.91 |
Other Current Assets | 1.53 | 1.53 | 1.85 | 0.94 | 0.66 |
Total Current Assets | 92.33 | 124.5 | 87.37 | 105.53 | 120.53 |
Property, Plant & Equipment | 58.57 | 72.52 | 75.47 | 92.89 | 123.51 |
Other Intangible Assets | 0.27 | - | 0.03 | 0.09 | 0.2 |
Long-Term Deferred Tax Assets | - | 1.87 | 1.77 | 1.85 | 2 |
Other Long-Term Assets | 275.64 | 277.62 | 276.55 | 279.31 | 285 |
Total Assets | 426.8 | 476.5 | 441.19 | 479.67 | 531.24 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.11 | 5.71 | 6.95 | 8.99 | 3.18 |
Accrued Expenses | 13.08 | - | - | - | - |
Short-Term Debt | 65 | - | 5 | - | 90 |
Current Portion of Long-Term Debt | 11.73 | 11.44 | 7.65 | 6.37 | 6.39 |
Current Portion of Leases | 11.07 | 13.53 | 13.38 | 12.64 | 13.82 |
Current Unearned Revenue | 1.04 | 1.58 | 1.51 | 11.69 | 1.2 |
Other Current Liabilities | 8.79 | 24.67 | 23.16 | 16.77 | 15.95 |
Total Current Liabilities | 114.81 | 56.93 | 57.65 | 56.45 | 130.54 |
Long-Term Debt | 46.72 | 58.46 | 69.91 | 57.53 | 63.82 |
Long-Term Leases | 21.51 | 31.77 | 29.93 | 35.69 | 47.27 |
Other Long-Term Liabilities | 3.58 | 3.53 | 3.57 | 2.51 | 2.93 |
Total Liabilities | 186.62 | 150.68 | 161.06 | 152.18 | 244.57 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 418.74 | 418.74 | 368.74 | 368.74 | 328.74 |
Additional Paid-In Capital | 90.07 | 90.07 | - | 96.17 | 0.17 |
Retained Earnings | -268.62 | -182.99 | -88.61 | -137.43 | -87.36 |
Comprehensive Income & Other | - | - | - | - | 45.12 |
Total Common Equity | 240.19 | 325.82 | 280.13 | 327.49 | 286.68 |
Shareholders' Equity | 240.19 | 325.82 | 280.13 | 327.49 | 286.68 |
Total Liabilities & Equity | 426.8 | 476.5 | 441.19 | 479.67 | 531.24 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 156.02 | 115.2 | 125.86 | 112.22 | 221.31 |
Net Cash (Debt) | -121.27 | -50.49 | -94.06 | -71.96 | -156.5 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -2.90 | -1.28 | -2.55 | -1.96 | -4.76 |
Filing Date Shares Outstanding | 41.87 | 41.87 | 36.87 | 36.87 | 32.87 |
Total Common Shares Outstanding | 41.87 | 41.87 | 36.87 | 36.87 | 32.87 |
Working Capital | -22.49 | 67.57 | 29.72 | 49.08 | -10.01 |
Book Value Per Share | 5.74 | 7.78 | 7.60 | 8.88 | 8.72 |
Tangible Book Value | 239.91 | 325.82 | 280.1 | 327.39 | 286.48 |
Tangible Book Value Per Share | 5.73 | 7.78 | 7.60 | 8.88 | 8.71 |
Buildings | 28.27 | 28.27 | 28.27 | 28.27 | 28.31 |
Machinery | 69.42 | 61.85 | 55.86 | 53.89 | 53.8 |
Leasehold Improvements | 5.46 | 7.12 | 7.26 | 7.26 | 31.1 |